Centre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Cell Biochem Biophys. 2013 May;66(1):37-43. doi: 10.1007/s12013-012-9395-5.
Molecular imaging employing (18)[F]FDG-PET/CT enables in-vivo visualization, characterisation and measurement of biological process in tumour at the molecular and cellular level. In oncology, this approach can be directly applied as translational biomarkers of disease progression. In this article, the improved roles of FDG as an in-vivo glycolytic marker which reflect biological changes across in-vitro cellular environment are discussed. New understanding in how altered metabolism via glycolytic downstream drivers of malignant transformation as reviewed below offers unique promise as to monitor tumour aggressiveness and hence optimize the therapeutic management.
采用（18）[F]FDG-PET/CT 的分子成像可实现肿瘤分子和细胞水平上生物过程的体内可视化、特征描述和测量。在肿瘤学中，这种方法可以直接用作疾病进展的转化生物标志物。本文讨论了 FDG 作为一种反映体外细胞环境中生物学变化的体内糖酵解标志物的作用的改善。下面综述了恶性转化的糖酵解下游驱动因素改变代谢的新认识，为监测肿瘤侵袭性和优化治疗管理提供了独特的前景。
